Publications by authors named "V Panagiota"

The aim of our study was to analyze the potential survival benefit associated with HSCT according to clinico-biological scores which incorporate molecular data (MIPSS70 and MIPSS70+V2) to facilitate decision-making in this context. One transplant (n=241) and one non-transplant cohorts (n=239) were used to test the hypothesis that PMF patients with higher risk molecular score benefit from HSCT. A weighted propensity score was applied to balance confounding factors with the transplanted cohort as reference.

View Article and Find Full Text PDF
Article Synopsis
  • Acute and chronic graft-versus-host disease (GvHD) are serious complications that can occur after allogeneic hematopoietic cell transplantation (alloHCT), and anti-T-lymphocyte globulin (ATLG) is commonly used to help prevent these issues.
  • A study involving 707 patients with myelofibrosis showed that those who received ATLG had significantly lower rates of acute GvHD (30%) compared to those who did not receive ATLG (56%) and also showed lower rates of severe chronic GvHD.
  • Overall, ATLG treatment was associated with better outcomes in terms of GvHD-free and relapse-free survival (GRFS) at six years (45% for AT
View Article and Find Full Text PDF

Splenomegaly is the clinical hallmark of myelofibrosis. Splenomegaly at the time of allogeneic hematopoietic cell transplantation (HCT) is associated with graft failure and poor graft function. Strategies to reduce spleen size before HCT especially after failure to Janus kinase (JAK) inhibition represent unmet clinical needs in the field.

View Article and Find Full Text PDF

Recent evidence revealed important interactions between clonal hematopoiesis (CH) and cellular therapies established for the treatment of hematologic malignancies. The impact of CH on safety, efficacy, and outcome of chimeric antigen receptor (CAR) T-cell therapy is currently under investigation. We analyzed 110 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (n = 105) or acute lymphoblastic leukemia (ALL) (n = 5), treated with Axicabtagene-Ciloleucel (39%), Tisagenlecleucel (51%), or Brexucabtagene autoleucel (10%).

View Article and Find Full Text PDF
Article Synopsis
  • TP53 mutations (TP53MTs) are linked to worse outcomes in various blood cancers, but their impact on patients with myelofibrosis undergoing stem cell transplants (HSCT) was previously unknown.
  • In a study of 349 patients, 13% had detectable TP53MTs, with those harboring multiple mutations experiencing significantly decreased median survival (1.5 years) compared to those without mutations (13.5 years).
  • Patients with single-hit TP53MT showed survival rates similar to those with no mutations, while multiple mutations indicated a high-risk profile, affecting both survival and relapse rates during treatment.
View Article and Find Full Text PDF